+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anti-Hypertensive Drugs - Global Strategic Business Report

  • PDF Icon

    Report

  • 326 Pages
  • April 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 1206745
The global market for Anti-Hypertensive Drugs was valued at US$25.3 Billion in 2024 and is projected to reach US$29.7 Billion by 2030, growing at a CAGR of 2.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Anti-Hypertensive Drugs Market - Key Trends and Drivers Summarized

The global market for anti-hypertensive drugs is a major segment within the pharmaceutical industry, driven largely by the widespread prevalence of hypertension, which affects approximately 1.5 billion people worldwide. Despite hypertension being one of the most common chronic diseases globally, there has been a noticeable decline in innovative research on blood pressure mechanisms and new treatments in recent years. This decline is particularly concerning given the rising burden of the disease, especially in low-income countries, coupled with ongoing issues of underdiagnosis and undertreatment in wealthier nations.

The demand for anti-hypertensive medications continues to grow, fueled by an aging population, increasing rates of obesity, sedentary lifestyles, and poor dietary choices such as high salt intake. In response, the market is seeing a shift towards the development of new drug therapies that offer better efficacy, reduced side effects, and improved patient compliance, such as combination therapies that incorporate multiple drugs in a single dosage form to simplify treatment regimens. Furthermore, advancements in genomics and biotechnology are paving the way for more personalized approaches to treatment, allowing for medications to be tailored to the genetic profiles of individual patients, enhancing the effectiveness of hypertension management.

Emerging economies are witnessing significant growth in access to anti-hypertensive treatments, driven by expanding middle classes and better health insurance coverage. This expansion is supported by government and healthcare initiatives aimed at increasing public awareness about the risks of high blood pressure and promoting effective management practices. Additionally, the rise of home health monitoring technologies, such as digital blood pressure monitors linked to smartphone apps, is promoting better patient engagement and adherence to treatment by enabling patients to monitor their condition in real-time. However, the industry also faces challenges such as stringent regulatory environments and pressure to reduce drug prices, which are pushing pharmaceutical companies to innovate in cost-effective drug production and distribution methods.

Report Scope

The report analyzes the Anti-Hypertensive Drugs market, presented in terms of market value (USD). The analysis covers the key segments and geographic regions outlined below.

Segments

Type (Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators, Other Types).

Geographic Regions/Countries

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Calcium Channel Blockers segment, which is expected to reach US$7.2 Billion by 2030 with a CAGR of a 3.2%. The ACE Inhibitors segment is also set to grow at 3.7% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $6.8 Billion in 2024, and China, forecasted to grow at an impressive 4.7% CAGR to reach $5.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Anti-Hypertensive Drugs Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Anti-Hypertensive Drugs Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Anti-Hypertensive Drugs Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Actelion Pharmaceuticals Ltd., AstraZeneca PLC, Bayer AG, Boehringer Ingelheim GmbH, Daiichi Sankyo Co., Ltd. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 143 companies featured in this Anti-Hypertensive Drugs market report include:

  • Actelion Pharmaceuticals Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Takeda Pharmaceutical Co., Ltd.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Anti-Hypertensive Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Hypertension Drives Anti-Hypertensive Drugs Market Growth
  • Technological Advancements in Drug Formulations Propel Market Innovation
  • Rising Adoption of Combination Therapies Expands Addressable Market Opportunity
  • Growth in Geriatric Population Strengthens Business Case for Anti-Hypertensive Drugs
  • Awareness, Early Screening & Focus on Hypertension Management Spur Market Growth
  • Integration of Telemedicine in Hypertension Care, a Key Trend Fueling Growth
  • Expansion of Pharmaceutical Industry in Emerging Markets Accelerates Market Growth
  • Increasing Use of Anti-Hypertensive Drugs in Diabetic Patients Sustains Market Growth
  • Rising Demand for Anti-Hypertensive Drugs in Obese Population. Here is the Story
  • Long-acting Anti-Hypertensive Drugs Grow in Popularity
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 2: World Historic Review for Anti-Hypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 3: World 15-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 5: World Historic Review for Diuretics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 6: World 15-Year Perspective for Diuretics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 8: World Historic Review for ACE Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 9: World 15-Year Perspective for ACE Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 11: World Historic Review for Calcium Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 12: World 15-Year Perspective for Calcium Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 14: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 15: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Beta-Adrenergic Blocker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 17: World Historic Review for Beta-Adrenergic Blocker by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 18: World 15-Year Perspective for Beta-Adrenergic Blocker by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Vasodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 20: World Historic Review for Vasodilators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 21: World 15-Year Perspective for Vasodilators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 22: World Anti-Hypertensive Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
III. MARKET ANALYSIS
UNITED STATES
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 24: USA Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 25: USA 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
CANADA
  • Table 26: Canada Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 27: Canada Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 28: Canada 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
JAPAN
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • Table 29: Japan Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 30: Japan Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 31: Japan 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
CHINA
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • Table 32: China Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 33: China Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 34: China 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
EUROPE
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • Table 35: Europe Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 36: Europe Historic Review for Anti-Hypertensive Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 37: Europe 15-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • Table 38: Europe Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 39: Europe Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 40: Europe 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
FRANCE
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • Table 41: France Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 42: France Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 43: France 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
GERMANY
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • Table 44: Germany Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 45: Germany Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 46: Germany 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
ITALY
  • Table 47: Italy Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 48: Italy Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 49: Italy 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
UNITED KINGDOM
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • Table 50: UK Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 51: UK Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 52: UK 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
SPAIN
  • Table 53: Spain Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 54: Spain Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 55: Spain 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
RUSSIA
  • Table 56: Russia Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 57: Russia Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 58: Russia 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
REST OF EUROPE
  • Table 59: Rest of Europe Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 60: Rest of Europe Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 61: Rest of Europe 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
ASIA-PACIFIC
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • Table 62: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 63: Asia-Pacific Historic Review for Anti-Hypertensive Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 64: Asia-Pacific 15-Year Perspective for Anti-Hypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • Table 65: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • Table 66: Asia-Pacific Historic Review for Anti-Hypertensive Drugs by Type - Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 67: Asia-Pacific 15-Year Perspective for Anti-Hypertensive Drugs by Type - Percentage Breakdown of Value Sales for Calcium Channel Blockers, ACE Inhibitors, Beta-Adrenergic Blocker, Diuretics, Vasodilators and Other Types for the Years 2015, 2025 & 2030
AUSTRALIA
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Anti-Hypertensive Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Actelion Pharmaceuticals Ltd.
  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Co., Ltd.
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Takeda Pharmaceutical Co., Ltd.

Table Information